Literature DB >> 21129857

CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer.

Tae Hyun Kim1, Sung-Sik Han, Sang-Jae Park, Woo Jin Lee, Sang Myung Woo, Tae Yoo, Sung Ho Moon, Seong Hoon Kim, Eun Kyung Hong, Dae Yong Kim, Joong-Won Park.   

Abstract

PURPOSE: In patients with pancreatic cancer treated with curative resection, we evaluated the effect of clinicopathologic parameters on early distant metastasis within 6 months (DM6m) to identify patients who might benefit from surgery. METHODS AND MATERIALS: The study involved 84 patients with pancreatic cancer who had undergone curative resection between August 2001 and April 2009. The parameters of gender, age, tumor size, histologic differentiation, T classification, N classification, pre- and postoperative carbohydrate antigen (CA) 19-9 level, resection margin, and adjuvant chemoradiotherapy were analyzed to identify the risk factors associated with DM6m.
RESULTS: Of the 84 patients, locoregional recurrence developed in 35 (41.7%) and distant metastasis in 58 (69%). Of the 58 patients with distant metastasis, DM6m had developed in 27 (46.6%). Multivariate analysis showed that preoperative CA 19-9 level was significantly associated with DM6m (p<.05). Of all 84 patients, DM6m was observed in 9.1%, 50%, and 80% of those with a preoperative CA 19-9 level of ≤100 U/mL, 101-400 U/mL, and >400 U/mL, respectively (p<.001).
CONCLUSIONS: The preoperative CA 19-9 level might be a useful predictor of DM6m and to identify those who would benefit from surgical resection.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21129857     DOI: 10.1016/j.ijrobp.2010.10.011

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-03-23       Impact factor: 12.969

2.  Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection?

Authors:  Atsushi Oba; Yosuke Inoue; Yoshihiro Ono; Shoichi Irie; Takafumi Sato; Yoshihiro Mise; Hiromichi Ito; Yu Takahashi; Akio Saiura
Journal:  Langenbecks Arch Surg       Date:  2019-11-28       Impact factor: 3.445

3.  CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer.

Authors:  Jennifer L Williams; Brian E Kadera; Andrew H Nguyen; V Raman Muthusamy; Zev A Wainberg; O Joe Hines; Howard A Reber; Timothy R Donahue
Journal:  J Gastrointest Surg       Date:  2016-04-25       Impact factor: 3.452

4.  A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?

Authors:  Toru Nakamura; Toshimichi Asano; Keisuke Okamura; Takahiro Tsuchikawa; Soichi Murakami; Yo Kurashima; Yuma Ebihara; Takehiro Noji; Yoshitsugu Nakanishi; Kimitaka Tanaka; Toshiaki Shichinohe; Satoshi Hirano
Journal:  J Gastrointest Surg       Date:  2018-09-21       Impact factor: 3.452

5.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2019-06       Impact factor: 13.787

6.  Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer.

Authors:  Yeon-Joo Kim; Woo Jin Lee; Sang Myung Woo; Tae Hyun Kim; Sung-Sik Han; Bo Hyun Kim; Sung Ho Moon; Sang Soo Kim; Young Hwan Koh; Sang-Jae Park; Joo-Young Kim; Dae Yong Kim; Joong-Won Park
Journal:  Radiat Oncol       Date:  2013-07-03       Impact factor: 3.481

7.  Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.

Authors:  Hao-Jun Shi; Chen Jin; De-Liang Fu
Journal:  World J Gastroenterol       Date:  2016-12-07       Impact factor: 5.742

8.  Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis.

Authors:  Gian Carlo Mattiucci; Alessio G Morganti; Francesco Cellini; Milly Buwenge; Riccardo Casadei; Andrea Farioli; Sergio Alfieri; Alessandra Arcelli; Federica Bertini; Felipe A Calvo; Silvia Cammelli; Lorenzo Fuccio; Lucia Giaccherini; Alessandra Guido; Joseph M Herman; Gabriella Macchia; Bert W Maidment; Robert C Miller; Francesco Minni; William F Regine; Michele Reni; Stefano Partelli; Massimo Falconi; Vincenzo Valentini
Journal:  Transl Oncol       Date:  2018-09-17       Impact factor: 4.243

Review 9.  Detecting Tumor Metastases: The Road to Therapy Starts Here.

Authors:  M E Menezes; S K Das; I Minn; L Emdad; X-Y Wang; D Sarkar; M G Pomper; P B Fisher
Journal:  Adv Cancer Res       Date:  2016-08-17       Impact factor: 6.242

10.  Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection.

Authors:  Niccolò Napoli; Emanuele Kauffmann; Concetta Cacace; Francesca Menonna; Davide Caramella; Carla Cappelli; Daniela Campani; Andrea Cacciato Insilla; Enrico Vasile; Caterina Vivaldi; Lorenzo Fornaro; Gabriella Amorese; Fabio Vistoli; Ugo Boggi
Journal:  Updates Surg       Date:  2020-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.